Home > Insider Trading > Filing (0000897423-18-000055)

Filing Details

Accession Number:: 0000897423-18-000055
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-07-26 14:59:47
Reporting Period:: 2018-07-24

Accepted Time:: 2018-07-26 14:59:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1398733	Aquestive Therapeutics Inc.	AQST	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1281933	K Douglas Bratton	201 Main Street Suite 1900 Fort Worth TX 76102	Yes	No	Yes	No
1723783	Bratton Capital Inc.	201 Main Street Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1723787	Bratton Capital Management, L.p.	201 Main Street Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1747211	Monoline Partners, L.p.	C/O Bratton Capital Management 201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-07-24	165,000	$15.00	165,000	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	75,085	Direct
Common Stock	2,249,077	Indirect	See Footnotes
Common Stock	2,213,314	Indirect	See Footnotes
Common Stock	4,032,907	Indirect	See Footnotes
Common Stock	2,755,541	Indirect	See Footnotes
Common Stock	87,455	Indirect	See Footnotes

Footnotes

These securities are beneficially owned by MonoLine Partners, L.P. ("MonoLine").
These securities are owned, as indicated, by MonoLine, MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities". Bratton Capital Management, L.P. ("Bratton Capital Management") is the general partner of each of the Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director of Bratton and has voting and investment power over all shares held by the Monoline Entities.
These securities are beneficially owned by MRX Partners.
These securities are beneficially owned by Monoline Rx.
These securities are beneficially owned by Monoline II.
These securities are beneficially owned by Monoline III.
These securities are beneficially owned by MonoSol Rx Genpar, L.P. ("Monosol"). Bratton is the general partner of Monosol. The Reporting Person, Douglas K. Bratton, is the sole director of Bratton and has voting and investment power over all shares held by Monosol.
Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.